Zymeworks ZYME Stock
Zymeworks Price Chart
Zymeworks ZYME Financial and Trading Overview
| Zymeworks stock price | 9.25 USD |
| Previous Close | 8.33 USD |
| Open | 8.3 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 8.12 - 8.41 USD |
| 52 Week Range | 4.11 - 10.8 USD |
| Volume | 353.5K USD |
| Avg. Volume | 499.78K USD |
| Market Cap | 524.28M USD |
| Beta (5Y Monthly) | 0.940492 |
| PE Ratio (TTM) | 3.01476 |
| EPS (TTM) | -1.72 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.07 USD |
ZYME Valuation Measures
| Enterprise Value | 221.1M USD |
| Trailing P/E | 3.01476 |
| Forward P/E | -6.142857 |
| PEG Ratio (5 yr expected) | -0.47 |
| Price/Sales (ttm) | 1.1751353 |
| Price/Book (mrq) | 1.1056976 |
| Enterprise Value/Revenue | 0.496 |
| Enterprise Value/EBITDA | 1.223 |
Trading Information
Zymeworks Stock Price History
| Beta (5Y Monthly) | 0.940492 |
| 52-Week Change | 33.93% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.8 USD |
| 52 Week Low | 4.11 USD |
| 50-Day Moving Average | 9.07 USD |
| 200-Day Moving Average | 7.92 USD |
ZYME Share Statistics
| Avg. Volume (3 month) | 499.78K USD |
| Avg. Daily Volume (10-Days) | 304.79K USD |
| Shares Outstanding | 64.17M |
| Float | 35.64M |
| Short Ratio | 11.1 |
| % Held by Insiders | 4.99% |
| % Held by Institutions | 101.11% |
| Shares Short | 5.57M |
| Short % of Float | 10.35% |
| Short % of Shares Outstanding | 8.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 38.68% |
| Operating Margin (ttm) | 39.15% |
| Gross Margin | 57.05% |
| EBITDA Margin | 40.50% |
Management Effectiveness
| Return on Assets (ttm) | 21.18% |
| Return on Equity (ttm) | 45.66% |
Income Statement
| Revenue (ttm) | 446.14M USD |
| Revenue Per Share (ttm) | 6.71 USD |
| Quarterly Revenue Growth (yoy) | 1756.89% |
| Gross Profit (ttm) | 203.78M USD |
| EBITDA | 180.72M USD |
| Net Income Avi to Common (ttm) | 172.61M USD |
| Diluted EPS (ttm) | 2.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 340.79M USD |
| Total Cash Per Share (mrq) | 5.31 USD |
| Total Debt (mrq) | 27.34M USD |
| Total Debt/Equity (mrq) | 5.77 USD |
| Current Ratio (mrq) | 6.334 |
| Book Value Per Share (mrq) | 7.389 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 116.33M USD |
| Levered Free Cash Flow (ttm) | 47.5M USD |
Profile of Zymeworks
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 114 East 4th Avenue |
| ZIP | V5T 1G4 |
| Phone | 604-678-1388 |
| Website | https://www.zymeworks.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 304 |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Q&A For Zymeworks Stock
What is a current ZYME stock price?
Zymeworks ZYME stock price today per share is 9.25 USD.
How to purchase Zymeworks stock?
You can buy ZYME shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zymeworks?
The stock symbol or ticker of Zymeworks is ZYME.
Which industry does the Zymeworks company belong to?
The Zymeworks industry is Biotechnology.
How many shares does Zymeworks have in circulation?
The max supply of Zymeworks shares is 70.57M.
What is Zymeworks Price to Earnings Ratio (PE Ratio)?
Zymeworks PE Ratio is now.
What was Zymeworks earnings per share over the trailing 12 months (TTM)?
Zymeworks EPS is -1.72 USD over the trailing 12 months.
Which sector does the Zymeworks company belong to?
The Zymeworks sector is Healthcare.
Zymeworks ZYME included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NYSE COMPOSITE (DJ) NYA | 17639.04 USD — |
-1.54
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}